AstraZeneca results: H1 and Q2 2026
AstraZeneca reported Q2 2026 Total Revenue of $15.38 billion, up 6% at actual rates and 5% at constant exchange rates (CER), driven by double-digit growth in Oncology. Core EPS increased 21% CER to $2.63, and the company reaffirmed its FY2026 guidance for mid-to-high single-digit revenue growth and low double-digit Core EPS growth. The company announced two major licensing agreements: acquiring worldwide rights to Zegfrovy from Dizal for an upfront $600 million, and rights to TQC3721 from Sino Biopharmaceutical for $200 million upfront.
Key figures
- Eps
- 2.63
- Revenue
- $15,384 million
- Guidance
- FY2026 Total Revenue increase mid-to-high single-digit %; Core EPS increase low double-digit %
- Revenue Yoy
- 6%
- Deal Value Usd
- 800000000
- H1 total revenue
- $30,672 million
- Interim dividend
- $1.06 per share
- Dizal upfront payment
- $600m
- Q2 core eps cer growth
- 21%
- Sino biopharmaceutical upfront payment
- $200m
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.